Related Experiment Video
Updated: Oct 13, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
GE11 Modified PLGA/TPGS Nanoparticles Targeting Delivery of Salinomycin to Breast Cancer Cells
Kaichun Li1, Liying Pang2, Xiaorong Pan1
1Department of Oncology, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, China.
Abstract:
Salinomycin (Sal) is a potent inhibitor with effective anti-breast cancer properties in clinical therapy. The occurrence of various side effect of Sal greatly limits its application. The epidermal growth factor receptor (EGFR) family is a family of receptors highly expressed in most breast cancer cells. GE11 is a dodecapeptide which shows excellent EGFR affinity. A series of nanoparticles derivatives with GE11 peptide conjugated PLGA/TPGS were synthesized. Nanoprecipitation method was used to prepare the Sal loaded nanoparticles at the optimized concentration. The characterization, targeting efficacy, and antitumor activity were detected both in vitro and in vivo. Encapsulation of Sal in GE11 modified PLGA/TPGS nanoparticles shows an improved therapy efficacy and lower systemic side effect. This represents the delivery system a promising strategy to enhance the therapeutic effect against EGFR highly expressed breast cancer.
Insights
This study developed novel nanoparticles to deliver Salinomycin (Sal) for breast cancer therapy. The GE11-modified nanoparticles target EGFR, enhancing efficacy and reducing side effects for improved breast cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Salinomycin (Sal) exhibits potent anti-breast cancer activity but is limited by side effects.
- Epidermal Growth Factor Receptor (EGFR) is highly expressed in many breast cancer cells, making it a therapeutic target.
- GE11 peptide demonstrates high affinity for EGFR, suggesting potential for targeted drug delivery.
Purpose of the Study:
- To synthesize and characterize novel nanoparticles for targeted delivery of Salinomycin to EGFR-overexpressing breast cancer.
- To evaluate the in vitro and in vivo efficacy and safety of Salinomycin-loaded GE11-conjugated PLGA/TPGS nanoparticles.
- To explore a promising nanodelivery strategy for enhancing breast cancer therapy.
Main Methods:
- Synthesis of GE11 peptide conjugated PLGA/TPGS nanoparticles using a nanoprecipitation method.
- Loading of Salinomycin into the nanoparticles at optimized concentrations.
- Comprehensive characterization of nanoparticle properties, including targeting efficacy.
- In vitro and in vivo assessment of antitumor activity and systemic side effects.
Main Results:
- Successful synthesis of Salinomycin-loaded GE11-modified PLGA/TPGS nanoparticles.
- Demonstrated targeting efficacy towards EGFR-expressing cancer cells.
- Enhanced therapeutic efficacy against breast cancer in both in vitro and in vivo models.
- Reduced systemic side effects compared to free Salinomycin.
Conclusions:
- GE11-modified PLGA/TPGS nanoparticles effectively encapsulate and deliver Salinomycin.
- This targeted nanodelivery system shows significant potential for improving breast cancer treatment outcomes.
- The strategy offers a promising approach to enhance therapeutic efficacy while minimizing adverse effects in EGFR-highly expressed breast cancers.
